Payment overview · 2025
General Payments
$521.34
14 reported records · 10 companies
Healthcare provider profile · identity verified
Marco A Martinez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · CUDAHY, CA · NPI 1700924909
Verified facts
What the public records show
CMS Open Payments records show Marco A Martinez, M.D. received $521.34 in general payments during 2025 across 14 reported records.
AKEBIA THERAPEUTICS INC accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auryxia, Rayaldee, Velphoro.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Auryxia by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Velphoro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $136.28 | 26.1% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $132.38 | 25.4% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.33 | 11.0% | 3 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $47.35 | 9.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.01 | 5.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.99 | 5.4% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $27.90 | 5.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.68 | 4.2% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.90 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.52 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.34 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryxia Normalized: auryxia |
Drug | AKEBIA THERAPEUTICS INC | $136.28 | 2 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $136.28 | 2 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $132.38 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $47.35 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $27.99 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auryxia auryxia |
2025 | Auryxia | 2024 | 48 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 60 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 91 |
| Furosemide | Furosemide | 285 | 98 |
| Metformin Hcl | Metformin Hcl | 285 | 90 |
| Losartan Potassium | Losartan Potassium | 278 | 92 |
| Hydralazine Hcl | Hydralazine Hcl | 263 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 85 |
| Omeprazole | Omeprazole | 229 | 82 |
| Gabapentin | Gabapentin | 221 | 67 |
| Alprazolam | Alprazolam | 212 | 41 |
| Kerendia | Finerenone | 181 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 66 |
| Simvastatin | Simvastatin | 174 | 50 |
| Valsartan | Valsartan | 163 | 56 |
| Lisinopril | Lisinopril | 153 | 49 |
| Farxiga | Dapagliflozin Propanediol | 146 | 42 |
| Nifedipine Er | Nifedipine | 142 | 49 |
| Glipizide | Glipizide | 138 | 44 |
| Prednisone | Prednisone | 131 | 56 |
| Tramadol Hcl | Tramadol Hcl | 131 | 49 |
| Carvedilol | Carvedilol | 130 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 43 |
| Famotidine | Famotidine | 118 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 21 |
| Alendronate Sodium | Alendronate Sodium | 99 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 35 |
| Benazepril Hcl | Benazepril Hcl | 93 | 30 |
| Lokelma | Sodium Zirconium Cyclosilicate | 93 | 41 |
| Sevelamer Carbonate | Sevelamer Carbonate | 93 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 25 |
| Calcitriol | Calcitriol | 90 | 33 |
| Azithromycin | Azithromycin | 86 | 70 |
| Ketoconazole | Ketoconazole | 84 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 67 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Megestrol Acetate | Megestrol Acetate | 78 | 26 |
| Clonazepam | Clonazepam | 77 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 24 |
| Temazepam | Temazepam | 77 | 12 |
| Linzess | Linaclotide | 76 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 27 |
| Calcium Acetate | Calcium Acetate | 69 | 27 |
| Meclizine Hcl | Meclizine Hcl | 68 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Eliquis | Apixaban | 65 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 23 |
| Ozempic | Semaglutide | 64 | 19 |
| Januvia | Sitagliptin Phosphate | 62 | 16 |
| Rayaldee | Calcifediol | 60 | 12 |
| Tradjenta | Linagliptin | 59 | 11 |
| Velphoro | Sucroferric Oxyhydroxide | 58 | 21 |
| Clonidine Hcl | Clonidine Hcl | 56 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 25 |
| Nystatin | Nystatin | 55 | 25 |
| Midodrine Hcl | Midodrine Hcl | 53 | 15 |
| Potassium Chloride | Potassium Chloride | 53 | 13 |
| Atenolol | Atenolol | 51 | 17 |
| Cephalexin | Cephalexin | 51 | 47 |
| Auryxia | Ferric Citrate | 48 | 11 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 45 | 11 |
| Procrit | Epoetin Alfa | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 39 | 30 |
| Trazodone Hcl | Trazodone Hcl | 39 | 13 |
| Clotrimazole | Clotrimazole | 38 | 12 |
| Lactulose | Lactulose | 38 | 15 |
| Febuxostat | Febuxostat | 36 | 12 |
| Prosol | Parenteral Amino Acid 20% No.1 | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 16 |
| Montelukast Sodium | Montelukast Sodium | 35 | 11 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Acetic Acid | Acetic Acid | 34 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 11 |
| Hydrocortisone | Hydrocortisone | 33 | 16 |
| Vascepa | Icosapent Ethyl | 33 | 11 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 14 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | 12 |
| Labetalol Hcl | Labetalol Hcl | 28 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 12 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Envarsus Xr | Tacrolimus | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Clarithromycin | Clarithromycin | 19 | 16 |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 19 | 13 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 11 |
| Mycophenolic Acid | Mycophenolate Sodium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.34 · 14 records | AKEBIA THERAPEUTICS INC | Auryxia, CRYSVITA, Filspari, JYNARQUE, OTEZLA, PURIFIED CORTROPHIN GEL, RAYALDEE, REPATHA, TARPEYO, VELPHORO, Vafseo, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auryxia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error